

WEST☐ Generate Collection

L52: Entry 8 of 9

File: DWPI

Apr 6, 1989

DERWENT-ACC-NO: 1989-114242

DERWENT-WEEK: 198915

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treatment of hypertension and other diseases - by chronic admin. of tryptophan or 5-hydroxy-tryptophan

INVENTOR: CADE, J R; FREGLY, M J

PATENT-ASSIGNEE:

ASSIGNEE

CODE

UNIV FLORIDA

UYFL

CADE J RRIDA

CADEI

FREGLY M JDA

FREGI

PRIORITY-DATA: 1987US-0102723 (September 30, 1987)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|--------------|-------------------|----------|-------|-------------|
| WO 8902737 A | April 6, 1989 | E | 084 | |
| CA 1328079 C | March 29, 1994 | | 000 | A61K031/405 |
| DE 3888827 G | May 5, 1994 | | 000 | A61K031/405 |
| EP 342211 A | November 23, 1989 | E | 000 | |
| EP 342211 B1 | March 30, 1994 | E | 004 | A61K031/405 |

DESIGNATED-STATES: DK FI JP NO US AT BE CH DE FR GB IT LU NL SE AT BE CH DE FR GB IT LI LU NL SE AT BE CH DE FR GB IT LI LU NL SE

CITED-DOCUMENTS:4.Jnl.Ref; US 4296119 ; US 4329356 ; WO 8503873 ; 1.Jnl.Ref

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|-------------|--------------------|----------------|------------|
| WO 8902737A | September 28, 1988 | 1988WO-US03302 | |
| CA 1328079C | September 30, 1988 | 1988CA-0579054 | |
| DE 3888827G | September 28, 1988 | 1988DE-3888827 | |
| DE 3888827G | September 28, 1988 | 1988EP-0909260 | |
| DE 3888827G | September 28, 1988 | 1988WO-US03302 | |
| DE 3888827G | | EP 342211 | Based on |
| DE 3888827G | | WO 8902737 | Based on |
| EP 342211A | September 28, 1988 | 1988EP-0909260 | |
| EP 342211B1 | September 28, 1988 | 1988EP-0909260 | |
| EP 342211B1 | September 28, 1988 | 1988WO-US03302 | |
| EP 342211B1 | | WO 8902737 | Based on |

INT-CL (IPC): A23K 1/16; A23L 1/30; A61K 31/40; A61K 31/405

ABSTRACTED-PUB-NO: EP 342211B

BASIC-ABSTRACT:

Treatment of hypertension, cardiac or renal hypertrophy, polydipsia, polyurea, stroke or atherosclerosis in humans or animals is effected by chronic admin. of L-tryptophan, L-5-hydroxytryptophan and/or their salts at a daily dose of 4-10g.

More specifically, the daily dose is 4-6g, esp. administered as a dietary supplement.

In an example, unilaterally nephrectomised rats were implanted with tubes contg. deoxycorticosterone acetate and given a feed contg. (a) no additive, (b) 2.5% tryptophan or (c) 5% tryptophan. After 5 weeks, urine output was (a) 268.2, (b) 241.4, (c) 164.6 ml/kg; urinary Na output was (a) 55.5, (b) 51.9, (c) 34.2 meq/kg; urinary K output was (a) 13.3, (b) 13.4, (c) 12.2 meq/kg; and urinary creatinine output was (a) 38.5, (b) 40.5, (c) 37.9 mg/kg.

ABSTRACTED-PUB-NO:

WO 8902737A

EQUIVALENT-ABSTRACTS:

Use of L-tryptophan and/or L-5-hydroxytryptophan and/or a pharmaceutically acceptable salt thereof as active ingredient(s) in the manufacture of a medicament for the treatment of atherosclerosis in a human or non-human animal.

CHOSEN-DRAWING: Dwg.0/22

TITLE-TERMS: TREAT HYPERTENSIVE DISEASE CHRONIC ADMINISTER TRYPTOPHAN HYDROXY TRYPTOPHAN

DERWENT-CLASS: B02 C02

CPI-CODES: B06-D01; B12-F01B; B12-F05; B12-G03; B12-H03; C06-D01; C12-F01B; C12-F05; C12-G03; C12-H03;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

D011 D601 H1 H100 H181 J0 J011 J1 J171 M280
M312 M321 M332 M343 M349 M371 M391 M412 M511 M520
M530 M540 M630 M640 M650 M781 M903 M904 M910 P523
P526 P723 P814

Specific Compounds

03943U 15668U

Registry Numbers

1704X 1724X 1711X 1714X

Chemical Indexing M2 *02*

Fragmentation Code

D011 D022 D601 H1 H100 H181 H4 H401 H441 H8
J0 J011 J1 J171 M280 M312 M321 M332 M343 M349
M371 M391 M412 M511 M520 M530 M540 M630 M640 M650
M781 M903 M904 M910 P523 P526 P723 P814

Specific Compounds

17528U 17529U

Registry Numbers

1704X 1724X 1711X 1714X

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0080U; 0110U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1989-050562